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HEXABROMOCYCLODODECANE AND 
TETRABROMOBISPHENOL A ALTER SECRETION OF 
INTERFERON GAMMA (IFNγ) FROM HUMAN IMMUNE CELLS
Haifa Almughamsi and Margaret M. Whalen
Department of Chemistry, Tennessee State University, Nashville, TN 37209
Abstract
Hexabromocyclododecane (HBCD) and tetrabromobisphenol A (TBBPA) are brominated flame 
retardant compounds used in a variety of applications including insulation, upholstery, and epoxy 
resin circuit boards. Interferon gamma (IFNγ) is an inflammatory cytokine produced by activated 
T and NK cells that regulates immune responsiveness. HBCD and TBBPA are found in human 
blood and previous studies have shown that they alter the ability of human natural killer (NK) 
lymphocytes to destroy tumor cells. This study examines whether HBCD and TBBPA affect the 
secretion of IFNγ from increasingly complex preparations of human immune cells; purified NK 
cells, monocyte-depleted (MD) peripheral blood mononuclear cells (PBMCs), and PBMCs. Both 
HBCD and TBBPA were tested at concentrations ranging from 0.05–5 μM. HBCD generally 
caused increases in IFNγ secretion after 24 h, 48 h, and 6 day exposures in each of the different 
cell preparations. The specific concentration of HBCD that caused increases as well as the 
magnitude of the increase varied from donor to donor. In contrast, TBBPA tended to decrease 
secretion of IFNγ from NK cells, MD-PBMCs and PBMCs. Thus, exposure to these compounds 
may potentially disrupt the immune regulation mediated by IFNγ. Signaling pathways that have 
the capacity to regulate IFNγ production (nuclear factor kappa B (NFκB), p44/42, p38, JNK) were 
examined for their role in the HBCD-induced increases in IFNγ. Results showed that the p44/42 
(ERK1/2) MAPK pathway appears to be important in HBCD-induced increases in IFNγ secretion 
from human immune cells.
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INTRODUCTION
Interferon-gamma (IFNγ) is a pro-inflammatory cytokine secreted by T cells, natural killer 
(NK) cells (NK), and monocytes ((Billiau and Matthys, 2009; Darwich et al., 2008; Kraaij et 
al., 2014). It regulates the inflammatory response in a sophisticated manner, including 
activation of growth and differentiation of T-cells, B-cells, macrophages, and NK cells 
(Schroder et al., 2004). In order to prevent loss of immune capability or the increased risks 
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associated with chronic inflammation, careful regulation of IFNγ is required (Zaidi & 
Merlino, 2011). Depending on the specific circumstances IFNγ may behave both in a pro-
tumorigenic and an antitumor manner. Cancer development will be avoided when IFNγ 
increases tumor cell death by macrophages, T cells, and NK cells. However, cancer could 
occur when there is stimulation of myeloid derived suppressor cell development by IFNγ 
(Zaidi & Merlino, 2011). IFNγ has the ability to cause chronic inflammation, which has 
been shown to further the development of some cancers such as gastrointestinal cancers 
(Macarthur et al., 2004).
Hexabromocyclododecane (HBCD) is a brominated flame retardant compound (Schecter et 
al., 2012). Expanded polystyrene, and extruded polystyrene are the main uses for this flame 
retardant, however it has also been used in textiles such as upholstery materials (Kajiwaraet 
al., 2009). HBCD exposure may have health effects on humans as it has been found in 
human blood serum (100 pg/g serum, which is approximately 0.16 nM) (Covaci et al., 2006; 
Knutsen et al., 2008). Studies in rats have shown that exposure to HBCD elevated liver and 
pituitary weight as well as cholesterol levels (van der Ven et al., 2006). Additionally, HBCD 
has been shown to be neurotoxic in mice (Eriksson et al., 2006). Human NK cells exposed to 
HBCD show decreased ability to lyse their target cells (cytolytic function) (Hinkson & 
Whalen, 2009). Additionally, they show decreases in cell surface proteins needed for 
cytolysis and activation of the mitogen activated protein kinase (MAPK), p44/42 (ERK1/2) 
(Cato et al., 2014; Hinkson &Whalen, 2010).
The flame retardant compound tetrabromobisphenol A (TBBPA) is mainly used in plastic, 
epoxy resin printed circuit boards, and other electronic equipment (Morose, 2006). It has 
been found in the environment and in wildlife such as fish (Yang et al., 2012). TBBPA has 
been found in human blood and tissue samples in limited amount (0.24 to 4.5 ng/g lipid that 
converts to about 0.002–0.033 nM) (Hagmar et al., 2000; Nagayama et al., 2001; Thomsen 
et al., 2002). Administration of TBBPA to young rats caused polycystic kidney lesions 
(Fukuda et al., 2004). TBBPA was able to compete with thyroid hormone, T4, for binding to 
human transthyretin (thyroid hormone transport protein) in vitro (Meerts et al., 2000). 
TBBPA, like HBCD, decreases the cytolytic function of human NK cells while decreasing 
cell surface proteins and activating p44/42 (Cato et al., 2014; Kibakaya et al., 2009)
IFNγ levels are regulated by a variety of signaling pathways, including mitogen activated 
protein kinases (MAPKs) and nuclear factor kappa B (NFκB) (Suk et al., 2001). 
Transcription regulators, CREB, ATF-2, and c-Jun, regulate IFNγ secretion by binding to the 
promoter of IFNγ to enhance gene expression in response to antigenic stimulation of T cells 
(Samten et al., 2008). Several factors induce CREB activation by phosphorylation including 
the MAPKs, p44/42 (ERK1/2) and p38 (via their activation of downstream kinases, RSKs 
and MAPKAP-kinases) (Shaywitz & Greenberg, 1999).
Secretion of several pro-inflammatory cytokines is altered in response to exposure to 
butyltin (BT) environmental contaminants. Secretion of IFNγ (Lawrence et al., 2015), IL-1β 
(Brown & Whalen, 2014), and TNF-α (Hurt et al., 2013) were all affected when immune 
cells were exposed to the BTs tributylin (TBT) or dibutyltin (DBT). Based on these facts, it 
is important to examine whether the brominated flame retardant compounds, HBCD and 
Almughamsi and Whalen Page 2













TBBPA, have the ability to alter the secretion of interferon gamma IFNγ from human 
immune cells.
In this study, immune cell preparations of increasing complexity were examined for the 
effects of HBCD and TBBPA exposures on the secretion of IFNγ. The cell preparations 
studied were: human NK cells, human monocyte-depleted (MD) peripheral blood 
mononuclear cells (PBMCs) (MD-PBMCs), and PBMCs. Using these increasingly 
reconstituted preparations of immune cells allows us to see whether the effects of the 
compounds vary dependent on the composition of the cell preparation. An additional goal of 
this study is to investigate signaling pathways that may be involved in any compound-
induced alterations in IFNγ secretion. Thus, additional studies were done where MD-
PBMCs were pre-treated with p44/42 (ERK 1/2) pathway inhibitor, JNK pathway inhibitor, 
p38 inhibitor, or NFκB inhibitor before exposure to HBCD.
MATERIALS AND METHODS
Preparation of PBMCs, and monocyte-depleted PBMCS
PBMCs were isolated from Leukocyte filters (PALL- RCPL or RC2D) obtained from the 
Red Cross Blood Bank Facility (Nashville, TN) as described in Meyer et al., 2005. 
Leukocytes were retrieved from the filters by back-flushing them with an elution medium 
(sterile PBS containing 5 mM disodium EDTA and 2.5% [w/v] sucrose) and collecting the 
eluent. The eluent was layered onto Ficoll-Hypaque (1.077g/mL) and centrifuged at 1200g 
for 50 min. Granulocytes and red cells pelleted at the bottom of the tube while the PBMCs 
floated on the Ficoll-Hypaque. Mononuclear cells were collected and washed with PBS 
(500g, 10min). Following washing, the cells were layered on bovine calf serum for platelet 
removal. The cells were then suspended in RPMI-1640 complete medium which consisted 
of RPMI-1640 supplemented with 10% heat-inactivated BCS, 2 mML-glutamine and 50 U 
penicillin G with 50 μg streptomycin/mL. This preparation constituted PBMCs. Monocyte-
depleted PBMCs (10-20% CD16+, 10-20 % CD56+, 70–80% CD3+, 3–5% CD19+, 2–20% 
CD14+) were prepared by incubating the cells in glass Petri dishes (150 × 15 mm) at 37 °C 
and air/CO2, 19:1 for 1 h. This cell preparation is referred to as MD-PBMCS cells.
Preparation of NK cells
NK cells were prepared from buffy coats (source leukocytes from healthy adult donors) 
purchased from Key Biologics, LLC (Memphis, TN). Highly purified NK cells were 
prepared using a rosetting procedure. RosetteSep human NK cell enrichment antibody 
cocktail (0.6–0.8 mL) (StemCell Technologies, Vancouver, British Columbia, Canada) was 
added to 45 mL of buffy coat. The mixture was incubated for 20 min at room temperature. 
Approximately 8 mL of the mixture was layered onto 4 mL of Ficoll-Hypaque (1.077 g/mL) 
(MP Biomedicals, Irvine, CA) and centrifuged at 1200 g for 50 min. NK cells were collected 
and washed twice with phosphate buffered saline (PBS) pH 7.2 and stored in complete 
media (RPMI-1640 supplemented with 10% heat-inactivated bovine calf serum (BCS), 2 
mM L-glutamine and 50 U penicillin G with 50 μg streptomycin/ml) at 1 million cells/mL at 
37 °C and air/CO2, 19:1. NK cells were enriched to greater than 85% CD16+/CD56+
Almughamsi and Whalen Page 3














HBCD and TBBPA were purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions 
were prepared as 100 mM solutions in dimethylsulfoxide (DMSO). Desired concentrations 
of either HBCD or TBBPA were prepared by dilution of the stock into media.
Inhibitor Preparation
Enzyme inhibitors were purchased from Fischer Scientific (Pittsburgh, PA). Each inhibitor 
was prepared from stock solution in DMSO. MEK 1/2, pathway inhibitor (PD98059), p38 
inhibitor (SB202190), NFκB inhibitor (BAY11-7085), and JNK inhibitor (JNK×BI78D3). 
All dilutions were made with cell culture media.
Cell Treatments
PBMCs, NK cells, and MD-PBMCs (at concentrations of 1.5 million cells/ mL) were treated 
with HBCD with appropriate DMSO control at concentrations from 0.05–5 μM for 24 h, 48 
h, or 6 days. Cells were treated with TBBPA with appropriate control at concentrations from 
0.05–5 μM for the same lengths of incubation as used with HBCD. After the incubations, the 
cells were pelleted and supernatants were collected and stored at −80 C until assaying for 
IFNγ.
For pathway inhibitor experiments, monocyte-depleted PBMCs were treated with enzyme 
inhibitors (and appropriate control) 1 h prior to adding HBCD at concentrations of 2.5, 1, 0.5 
μM HBCD for 24h. After the incubations, the cells were pelleted and supernatants were 
collected and stored at −70 C until assaying for IFNγ.
Cell Viability
Cell viability was assessed at the end of each exposure period. Viability was determined 
using the trypan blue exclusion method. Briefly, cells were mixed with trypan blue and 
counted using a hemocytometer. The total number of cells and the total number of live cells 
were determined for both control and treated cells to determine the percent viable cells.
IFNγ Secretion Assay
IFNγ levels were measured using the BD OptEIA™ Human IFNγ enzyme-linked 
immunosorbent assay (ELISA) kit (BD-Pharmingen, San Diego, CA). Briefly, a 96-well 
micro well plate, designed for ELISA (Fisher, Pittsburgh, PA), was coated with a capture 
antibody for IFNγ and incubated overnight at 4 °C. Following the incubation, the capture 
antibody was removed by washing the plate three times with wash buffer (PBS and 0.05% 
Tween-20). Blocking solution (PBS containing 10% bovine calf serum) was added to each 
well and incubated at room temperature for 1 h followed by three washes. Cell supernatants 
and IFNγ standards were added to the plate which was sealed and incubated for 2 h at room 
temperature. Following this incubation, the plate was washed five times and then incubated 
for 1 h with a detection antibody linked to horseradish peroxidase (HRP). The detection 
antibody-HRP complex was removed by seven washes and the plate was incubated for 30 
min with substrate. This incubation was ended by addition of acid and the absorbance was 
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measured at 450 nm on a Thermo Labsystems Multiskan MCC/340 plate reader (Fisher 
Scientific).
Statistical Analysis
Statistical analysis of the data was performed by using ANOVA and Student's t test. Data 
were initially compared within a given experimental setup by ANOVA. A significant 
ANOVA was followed by pair wise analysis of control versus exposed data using Student's t 
test, a p value of less than 0.05 was considered significant.
RESULTS
Viability of NK cells, MD-PBMCs, and PBMCs exposed to HBCD and TBBPA
Exposure of all cell preparations to 0.05–5 μM HBCD or TBBPA for all length of exposure 
had no significant effect on their viability as compared to the control (data not shown, 
available in electronic supplement).
Viability of monocyte-depleted PBMCs treated with selective enzyme inhibitors and then 
exposed to HBCD
Exposure of MD-PBMCs to pathway inhibitors 1 hour prior to adding the appropriate 
concentrations of HBCD caused no significant alterations in cell viability (data not shown, 
available in electronic supplement).
Effects of HBCD Exposure on Secretion of IFNγ by NK cells
Table 1 shows the effects of exposing highly purified NK cells to 0, 0.05, 0.1, 0.25, 0.5, 1, 
2.5, and 5 μM HBCD for 24 h, 48 h, and 6 days on IFNγ secretion from 4 donors (KB=Key 
Biologic buffy coat). There were significant increases in IFNγ secretion from NK cells from 
all donors examined after all lengths of exposure to certain concentrations of HBCD. 
Concentrations that caused increases varied from one donor to the next. For instance, the 
cells from donor KB179 showed significant increases after a 24 h exposure to 0.1 −1μM 
HBCD, while NK cells from donor KB180 showed increased secretion of IFNγ when 
exposed to 0.05–2.5 μM HBCD. Additionally, the magnitude of the increase in secretion 
varied among donors. For example, exposure to 0.1 μM HBCD for 24 h caused a 2.7 fold 
increase in IFNγ secretion in cells from KB179 while that same concentration of HBCD 
caused a 114 fold increase from KB180 cells. A similar pattern of results was seen after 48 h 
and 6 d exposures. Figure 1A shows the effects of HBCD exposures on IFNγ secretion at 
each of the time points for an individual donor (KB182).
Effects of HBCD Exposure on Secretion of IFNγ by MD-PBMCs
When MD-PBMCs (predominantly NK and T cells) were exposed to HBCD for 24 h, 48 h, 
and 6 d (F=filter obtained from the Red Cross) there were statistically significant increases 
in IFNγ secretion induced at several concentrations of HBCD for all donors with variation in 
the fold increase among different donors (Table 2). For instance, after 24 h, cells from F202 
showed 27.4, 51.9, 18.4, 13.9, and 7.6, increases at the 0.1, 0.25, 0.5, 1 and 2.5 μM 
concentrations, respectively, while F212 showed 1.9, 2.4, 3.9, 2.4, 9.8, and 5.2 fold, 
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increases at those same concentrations. Figure 1B shows the effect of HBCD exposures on 
IFNγ secretion at each of the time points for an individual donor (F212).
Effects of HBCD Exposure on Secretion of IFNγ by PBMCs
PBMCs exposed to HBCD also showed significant increases in IFNγ at all lengths of 
exposure (Table 3). As was seen with NK cells and MD-PBMCs, the concentrations at 
which significant increases occurred varied among the 5 donors tested. For instance after a 
24 h exposure to HBCD, the cells from donor F192 treated with 0.05, 0.25, and 2.5 μM 
HBCD showed significant increases of 1.8, 2.6, and 1.5 fold respectively after 24 h, while 
cells from donor F193 showed significant increases of 10.1, 3.7, 2.6, and 2.1 fold at 0.05, 
0.1, 0.25, and 2.5 μM HBCD concentrations, respectively. Figure 1C shows the effects of 
HBCD exposures at each of the lengths of exposure for an individual donor (F189).
Effects of TBBPA Exposure on Secretion of IFNγ by NK cells
Table 4 shows the effects of exposing highly purified NK cells to 0, 0.05, 0.1, 0.25, 0.5, 1, 
2.5, and 5 μM TBBPA for 24 h, 48 h, and 6 d on the secretion of IFNγ. A 24 h TBBPA 
exposure caused decreases in IFNγ secretion. Concentrations that caused decreases varied 
from one donor to the next. For instance, the cells from donor KB129 showed significant 
decreases after a 24 h exposure to 0.25, 0.5, 1,and 5 μM TBBPA, while NK cells from donor 
KB183 showed decreased secretion of IFNγ when exposed to all concentrations TBBPA 
tested. Similar results were seen in 48 h and 6 d of exposures to TBBPA. Figure 2A shows 
the effects of TBBPA exposures at each of the lengths of exposure for an individual donor 
(F183).
Effects of TBBPA Exposure on Secretion of IFNγ by MD-PBMCs
As with NK cells, there were significant decreases in secretion of IFNγ from MD-PBMCs at 
every length of exposure to TBBPA (Table 5). Concentrations that caused decreases varied 
somewhat among donors. For instance, the cells from donor F175 and F177 showed 
significant decreases in IFNγ secretion after exposure to 0.1 −5μM TBBPA while those from 
F180 showed a significant decrease only at 5 μM. Figure 2B shows the effects of TBBPA 
exposures at each of the lengths of exposure for an individual donor (F177).
Effects of TBBPA Exposure on Secretion of IFNγ by PBMCs
PBMCs showed significant decreases in IFNγ secretion when exposed to higher 
concentrations of TBBPA (Table 6). Concentrations that caused decreases varied from one 
donor to the next at each time point. For instance, the cells from donor F188 showed 
significant decreases after a 24 h exposure to 0. 5 −5 μM TBBPA, while PBMCs from donor 
F193 showed decreased secretion of IFNγ when exposed to 0.25–5 μM TBBPA. Figure 2C 
shows the effects of TBBPA exposures at each of the lengths of exposure for an individual 
donor (F188).
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Effects of HBCD Exposure on Secretion of IFNγ by MD-PBMCs with Selective Enzyme 
Inhibitors
NFκB Inhibitor (BAY 11-7085)—The effects of exposures to 0.5, 1, and 2.5 μM HBCD 
on secretion of IFNγ from MD-PBMCs where NFκB had been inhibited with BAY 11-7085 
(BAY) (0.325 μM) are shown in Table 7. BAY inhibited baseline IFNγ secretion due to its 
necessary role in IFNγ production. BAY diminished the ability of HBCD to increase IFNγ 
secretion from MD-PBMCs in the majority of donors. In Figure 3A (representative data 
from F273) we see there is 5.8 fold increases when MD-PBMCs are exposed to 2.5 μM 
HBCD in the absence of NFκB inhibitor. When the inhibitor is present this same HBCD 
exposures causes 2.2 fold increases in IFNγ secretion. These results suggest that NFκB 
inhibitor may be involved HBCD-induced increases in IFNγ secretion but its role may vary 
depending on the status of the donor. For all inhibitor studies the fold increase is determined 
from the appropriate control.
Mitogen activated protein kinase kinase (MAP2K), MEK, Inhibitor (PD98059)
The effects of exposures to 0.5, 1, and 2.5 μM HBCD on secretion of IFNγ from MD-
PBMCs where MEK had been inhibited with PD98059 (50 μM) are shown in Table 7. 
PD98059 had variable effects on baseline IFNγ secretion. Cells exposed to HBCD showed a 
lower fold increase in IFNγ secretion in the presence of the inhibitor. In Figure 3B 
(representative data from F253) we see there are 3.1, 4.9, and 7.5 fold increases when MD-
PBMCs are exposed to 0.5, 1, and 2.5 μM HBCD in the absence of p44/42 pathway 
inhibitor. When the inhibitor (PD98059) is present those same HBCD exposures causes 1.5, 
1.5, and 2.5 fold increases in IFNγ secretion. This indicates that the p44/42 pathway is a 
likely target of HBCD that leads to increased secretion of IFNγ.
p38 Inhibitor (SB202190)—Inhibition of p38 (SB202190, 50 μM) did not block the 
HBCD-induced increases in IFNγ (Table 7). In fact it tended to increase the effect of HBCD 
(every donor showed an enhanced increase at a minimum of one concentration of HBCD). In 
Figure 3C (representative data from F255) there are 2.4, 1.8, and 2.6 fold increases when 
MD-PBMCs are exposed to 0.5, 1, and 2.5 μM HBCD in the absence of p38 inhibitor. When 
the inhibitor is present, those same HBCD exposures are able to cause 9.4, 6.3, and 5.8 fold 
increases in IFNγ secretion.. Thus, p38 doesn't seem to be utilized by HBCD to induce 
increases in IFNγ secretion and it appears to be inhibiting the ability of HBCD to increase 
IFNγ.
JNK Inhibitor (BI78D3)—When JNK was inhibited by BI78D3 (0.05 μM), all donors 
continued to show an increase IFNγ secretion in response to HBCD (Table 7). Figure 3D, 
(representative data from F278) shows that there were 1.6, 3.9, and 2.2 fold increases in 
IFNγ secretion when MD-PBMCs were exposed to 0.5, 1, and 2.5 μM HBCD in the absence 
of the JNK inhibitor and 14.8, 19.1, and 3.3 fold increases in its presence. These results 
indicate that JNK pathway is not a target for the HBCD-induced increase in IFNγ secretion.
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IFNγ is a pro inflammatory cytokine and a critical immune system regulator (Schroder et al., 
2004). It inhibits intracellular viral replication (Frese et al., 2002) and regulates activation of 
specific immune cells ((Schroder et al., 2004). Inappropriately elevated levels of it may 
contribute to development of atherosclerotic disease contributing to myocardial infarction 
and stroke (Gupta et al., 1997). HBCD and TBPPA are used as flame retardants and 
significantly contaminate the environment, with detectable levels being found in human 
tissues (Covaci et al., 2006; Knutsen et al., 2008; Hagmar et al., 2000; Nagayama et al., 
2001; Thomsen et al., 2002). Both compounds are able to decrease the lytic function and cell 
surface protein expression of human NK cells (Hinkson & Whalen, 2009; Hinkson & 
Whalen, 2010; Kibakaya et al., 2009; Hurd & Whalen, 2011). This inhibition of NK lytic 
function may be due to their ability to induce activation/phosphorylation of MAPKs and 
MAP2Ks (Cato et al., 2014). Other environmental contaminants such as tributyltin (TBT) 
and dibutyltin (DBT) (Kimbrough, 1976) that decrease NK lytic function (Dudimah et al., 
2007a,b), while activating the MAPK pathway (Aluoch et al., 2006; Odman- Ghazi et al., 
2010), have been shown to alter IFNγ secretion from human immune cells (Lawrence et al., 
2015). Thus, it is crucial to determine whether HBCD and TBBPA are also able to alter the 
secretion of IFNγ from human immune cells.
Different donors showed varied baseline secretion of IFNγ in each of the cell preparations. 
However, each of the cell preparations (PBMCs, MD-PBMCs, and NK cells) had similar 
responses to exposures to HBCD. For instance, when highly purified NK cells were exposed 
to 0.05–5 μM HBCD, there were significant increases in secretion of IFNγ. The ability of 
HBCD to increase IFNγ levels did not seem to change as the complexity of the cell 
preparations increased, as both MD-PBMCs and PBMCs also showed similar patterns of 
increased IFNγ secretion in response to HBCD. Additionally, the maximum fold increase in 
each cell preparations (NK cells, MD-PBMCs, and PBMCs) occurred at a similar range of 
HBCD concentration after 24 h. For instance, in NK cells (KB182) the range of maximum 
fold increases of IFNγ secretion occurred at 0.1–1 μM HBCD while in MD-PBMCs (F212) 
the range of maximum fold increases of IFNγ secretion was 0.1–2.5 μM. The most complex 
cell preparation PBMCs (F193) had a maximum fold increase in the range of (0.05–2.5μM) 
HBCD.
In general, the secretion of IFNγ for all cell types showed a significant decrease in response 
to TBBPA exposure at a minimum of one concentration and at least one length of exposure 
from each type of cell preparation. For instance, the cells from donor KB 129 showed 
significant decreases after a 24 h exposures to 0.25, 0.5, 1, and 5 μM TBBPA while the cells 
from MD-PBMCs donor F175 showed significant decreases after 24 h exposures to 0.1–5 
μM TBBPA. Additionally, the cells from PBMCs (F188) showed significant decreases after 
a 24 h exposure to 0.5 –5 μM TBBPA. Importantly the viability of the cells was not 
significantly affected by treatment with either of the compounds providing evidence that the 
effects on secretion were not due to death of the cells
While HBCD predominantly caused increases in IFNγ secretion, TBBPA generally caused 
no change or decreases in secretion. Interestingly, HBCD and TBPA also differ in their 
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capacity to activate MAPKs. HBCD is able to activate p44/42 while TBBPA activates both 
p44/42 and p38 (Cato et al., 2014). Thus, at least part of the difference in the effects of these 
2 compounds on IFNγ secretion may be due to their ability to differentially activate MAPKs. 
A previous study examining the effect of both TBT and DBT on secretion of IFNγ from 
immune system cells, showed that both TBT and DBT decreased IFNγ secretion at the 
highest concentrations while they both increased its secretion at lower concentrations 
(Lawrence et al., 2015).
After demonstrating that HBCD-induced increases in IFNγ secretion were seen, selected 
inhibitors were used to determine what signaling pathway(s) may be involved in HBCD-
induced alteration in IFNγ secretion. IFNγ secretion is known to be regulated by the p44/42 
pathway in immune cells (Girart et al., 2007). It appears that the p44/42 (ERK1/2) pathway 
is needed for HBCD-induced increases in IFNγ as inhibition of this pathway prior to HBCD 
exposure resulted in a diminished response to HBCD. The NFκB pathway is an important 
regulator of inflammatory responses, such as IFNγ production (Oeckinghaus & Ghosh, 
2009). The current results indicate that the role of NKκB in the HBCD-induced increases in 
IFNγ secretion appears to vary depending on the donor. Previous studies have shown that 
additional MAPKs such as p38 and JNK also to regulate IFNγ secretion (Rincón et al., 
2000). Here we found that inhibition of either p38 or JNK does not block the ability of 
HBCD to increase IFNγ secretion. In fact, inhibition of p38 caused HBCD to be more 
effective at increasing IFNγ secretion. Previous studies have shown that p44/42 activation by 
TBT is involved in TBT-induced increases in IL-1β secretion (Brown & Whalen, 2014).
It is noteworthy that the specific effects of the compounds varied in cells from different 
donors. The cells from all donors showed similar effects, however, the magnitude of the 
effect as well as the specific concentrations at which it occurred varied. This indicates that 
while the immune cells from all donors were affected by the compounds, there were 
individual differences. The concept of personalized medicine has become important in the 
treatment of a number of disease, most especially cancer (Madureira & de Mello, 2014). The 
results from this study indicate that there may individualized responses to environmental 
toxicants, which may be important in assessing risk.
In summary, the current study indicates that the secretion of IFNγ in the three human 
immune cell preparations studied is altered by exposures to HBCD and TBBPA. HBCD 
showed predominantly increases in IFNγ secretion. TBBPA generally caused no change or 
decreases in secretion. These results suggest that both of these flame retardant compounds 
are able to disrupt secretion of IFNγ from increasingly complex human immune cell 
preparations. These effects maintained even in the most complex preparation that we 
examined. This is important in that this preparation is more physiologically relevant. Based 
on that fact IFNγ is necessary for appropriate immune response to viral infection, any 
decrease in IFNγ due to exposure to these compounds could lead to an individual becoming 
more susceptible to viral infection. While compound-induced increases in IFNγ may cause 
inappropriate inflammation. Such inflammation can lead to pathologies such as 
atherosclerotic disease (Gupta et al., 1997) and potentially increased tumor growth 
(Macarthur et al., 2004). Thus, these results may indicate that these compounds could affect 
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human diseases. Additionally we showed that p44/42 MAPK is involved in the HBCD-
induced increases in IFNγ secretion.
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Effects of 24 h, 48 h and 6 day exposures to HBCD on IFNγ secretion from human NK cells, 
monocyte-depleted PBMCs, and PBMCs. A) NK cells exposed to 0.05-5 μM HBCD (donor 
KB182). B) Monocyte-depleted PBMCs exposed to 0.05-5 μM HBCD (donor F204). C) 
PBMCs exposed to 0.05-5 μM HBCD (donor F193).
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Effects of 24 h, 48 h and 6 day exposures to TBBPA on IFNγ secretion from human NK 
cells, monocyte-depleted PBMCs, and PBMCs. A) NK cells exposed to 0.05-5 μM TBBPA 
(donor KB183). B) Monocyte-depleted PBMCs exposed to 0.05-5 μM TBBPA (donor 
F180). C) PBMCs exposed to 0.05-5 μM TBBPA (donor F186).
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Effects of 24 h exposure to 0.5, 1, and 2.5 μM HBCD on IFNγ secretion from monocyte-
depleted PBMCs treated with selective enzyme inhibitors in an individual donor. A) NFκB 
Inhibitor (BAY 11-7085) (donor F273).B) MEK ½(p44/42) Inhibitor (PD98059) (donor 
F254).C) P38 Inhibitor (SB202190) (donor F254).D) JNK inhibitor (donor F271).
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Table 1
Effects of 24 h, 48 h, 6 day exposures to HBCD on IFNγ secretion from NK cells.
24 h Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM KB-179 KB-180 KB-181 KB-182
0 522±67 23±6 19±0.9 160±20
0.05 611±299 1468±1233 12±3* 170±9
0.1 1400±93* 2629±179* 7±0.8* 517±63*
0.25 1883±174* 1956±993 22±2 638±55*
0.5 4400±73* 1151±1222 9±3* 2055±65*
1 3233±76* 661±240* 55±11* 5182±319*
2.5 206±42* 195±149 135±8* 1120±75*
5 89±82* 18±4 50±4* 22±8*
48 h Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM KB-179 KB-180 KB-181 KB-182
0 1012±213 460±27 10±0.8 256±4
0.05 1687±503 933±385 12±1 243±92
0.1 2920±346* 1263±102* 15±3.2 906±98*
0.25 5695±482* 1170±111* 23±2* 1550±84*
0.5 12437±166* 1091±267 20±3* 2146±85*
1 12787±279* 808±249 60±2* 6118±253*
2.5 112±115* 310±188 1042±3* 6140±408*
5 0±58* 92±42* 66±0.9* 69±13*
6 day Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM KB-179 KB-180 KB-181 KB-182
0 3246±177 478±17 10±2 383±10
0.05 4438±1634 521±18* 12±2 333±60
0.1 4794±250* 394±25* 4±0.6* 465±44
0.25 8438±476* 660±25* 18±0.5* 660±88*
0.5 15184±645* 615±13* 23±3* 1607±231*
1 17015±128* 551±17* 106±3* 8825±1197*
2.5 715±166* 21±23* 1348±76* 9653±403*
5 351±104* 8±11* 267±14* 3655±43*
Values are mean±S.D. of triplicate determinations,
*
indicates a significant difference from control (p<0.05).
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Table 2
Effects of 24 h, 48 h, 6 day exposures to HBCD on IFNγ secretion from MD-PBMCs cells.
24 h Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM F196 F-197 F-198 F-202 F-204 F-212
0 2395±163 38±2 46±16 57±23 98±27 32±0.7
0.05 1777±309 193±30* 971±834 1362±1280 203±70 50±12
0.1 1910±133* 160±34* 1479±290* 1565±355* 228±109 62±6*
0.25 1219±151* 150±22* 1940±247* 2963±1054* 207±16* 78±11*
0.5 2628±65 140±31* 1150±788 1050±270* 82±11 125±9*
1 2268±60 172±61 479±307 790±216* 234±21* 77±15*
2.5 3406±139* 56±35 371±65* 433±116* 373±63* 314±9*
5 1465±10* 43±6 148±12* 75±37 238±24* 165±12*
48 h Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM F-196 F-197 F-198 F-202 F-204 F-212
0 2750±151 61±2 141±37 213±4 165±6 81±29
0.05 1924±51* 75±4* 81±25 388±275 244±105 222±185
0.1 2172±115* 207±100 150±33 593±232 356±52* 243±4*
0.25 4636±135* 120±8* 176±83 538±29* 507±36* 214±44*
0.5 4513±76* 126±8* 130±43 472±52* 440±167 299±37*
1 5559±96* 267±6* 208±42 901±48* 528±60* 330±30*
2.5 4381±532* 247±8* 444±35* 3044±27* 851±15* 2338±380*
5 2804±17 0±1* 330±41* 222±13 404±41* 1239±49*
6 day Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM F-196 F197 F-198 F-202 F-204 F-212
0 1831±33 119±0.3 44±14 423±95 148±17 113±8
0.05 1050±248* 95±7* 122±127 4176±3447 176±24 488±263
0.1 1229±519 106±14 65±20 2377±2401 156±32 776±163*
0.25 2319±619 120±17 92±47 933±289 147±40 639±118*
0.5 1729±60 157±30 43±7 1013±126* 240±11* 516±105*
1 4676±1600 521±80* 62±15 2034±262* 325±12* 315±27*
2.5 2362 ±112* 494±91* 262±83* 2030±74* 626±85* 4011±398*
5 1587±68* 8.2±1.3* 736±18* 234±31 476±10* 617±12*
Values are mean±S.D. of triplicate determinations,
*
indicates a significant difference from control (p<0.05).
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Table 3
Effects of 24 h, 48 h, 6 day exposures to HBCD on IFNγ secretion from PBMCs cells
24 h Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM F-187 F-189 F-192 F-193 F-195
0 46±9 416±29 1001±18 118±23 959±10
0.05 123±33* 2008±376* 1824±116* 1190±341* 1127±181
0.1 103±20* 2304±250* 1150±165 432±77* 916±52
0.25 140±15* 2504±102* 2557±175* 306±53* 972±27
0.5 183±24* 2997±325* 1001±232 304±107 1420±59*
1 263±13* 4229±84* 1037±57 268±96 1229±181
2.5 238±8* 7292±242* 1457±14* 251±32* 1027±33
5 274±25* 847±65* 396±17* 91±14 577±20*
48 h Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM F-187 F-189 F-192 F-193 F-195
0 100±13 465±13 889±37 763±27 598±13
0.05 359±88* 1146±57* 2394±359* 1198±154* 1095±55*
0.1 400±237 1130±22* 1604±235* 1424±216* 1471±33*
0.25 288±52* 1607±21* 1735±38* 1120±31* 846±62*
0.5 361±117 2549±129* 1878±184* 1346±173* 728±124
1 203±77 3322±41* 1505±67* 1591±86* 643±38
2.5 778±98* 6577±127* 421±21* 2044±72* 886±13*
5 1035±96* 770±20* 243±23* 1487±56* 248±46*
6 day Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM F187 F-189 F-192 F-193 F-195
0 17±7 236±9 2791±48 1404±30 1217±107
0.05 58±23 1746±132* 1316±777 341±23* 1468±633
0.1 23±10 1600±164* 2170±475 874±49* 194±40*
0.25 37±18 2060±85* 1701±246* 617±28* 1309±269
0.5 45±1* 2057±689* 2170±622 959±65* 1199±81
1 85±5* 2448±372* 1927±413 1052±28* 1853±51*
2.5 191±25* 2051±57* 809±86* 1274±35* 1519±94*
5 225±7* 490±102* 563±52* 481±8* 1209±1437
Values are mean±S.D. of triplicate determinations,
*
indicates a significant difference from control (p<0.05).













Almughamsi and Whalen Page 19
Table 4
Effects of 24 h, 48 h, 6 day exposures to TBBPA on IFNγ secretion from NK cells
24 h Interferon gamma secreted in pg/mL (mean±S.D.)
[TBBPA] μM KB-129 KB-130 KB-181 KB-183 KB-184
0 378±12 8497±206 0±1.9 1147±41 39±2
0.05 790±77* 8027±268 0.3±0.3 299±10* 29±2*
0.1 382±55 7060±227* 0.2±0.8 310±4* 66±3*
0.25 45±61* 1963±67* 0±0.3 254±49* 22±3*
0.5 0±39* 0±17* 0±0.8 73±15* 5±1*
1 0±64* 0±31* 0±0.6 47±1* 4±3*
2.5 0±3* 0±6* 0±1.8 39±11* 0±5*
48 h Interferon gamma secreted in pg/mL (mean±S.D.)
[TBBPA] μM KB-129 KB-130 KB-181 KB-183 KB-184
0 3347±69 11568±163 22±0.4 1958±37 208±9
0.05 3147±275 11882±727 20±2 447±17* 188±101
0.1 1357±296* 11045±184* 16±1.5* 368±11* 270±32
0.25 364±124* 4960±31* 22±2.3 133±12* 172±4*
0.5 92±79* 557±16* 22±1 29±6* 91±12*
1 24±94* 0±10* 15±2* 12±8* 76±15*
2.5 0±19* 13±28* 12±1* 3±9* 38±4*
5 0±12* 10±13* 13±0.4* 3±4* 32±7*
6 day Interferon gamma secreted in pg/mL (mean±S.D.)
[TBBPA] μM KB-129 KB-130 KB-181 KB-183 KB-184
0 6800±176 11687±290 27±0.7 2248±39 91±2
0.05 3573±107* 12607±545 31±3 987±67* 148±14*
0.1 2243±136* 10480±128* 36±1* 742±32* 175±17*
0.25 363±93* 3810±318* 37±1.4* 468±20* 102±14
0.5 0±137* 678±30* 32±0.7* 135±13* 49±4*
1 0±117* 60±35* 25±1.1 135±5* 25±8*
2.5 0±46* 32±19* 23±0* 125±18* 13±3*
5 0±55* 25±5* 26±0.4* 133±3* 17±1*
Values are mean±S.D. of triplicate determinations,
*
indicates a significant difference from control (p<0.05).
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Table 5
Effects of 24 h, 48 h, 6 day exposures to TBBPA on IFNγ secretion from MD-PBMCs cells.
24 h Interferon gamma secreted in pg/mL (mean±S.D.)
[TBBPA] μM F-175 F-177 F-180
0 213±10 109±2 64±2
0.05 190±28 87±27 1302±195*
0.1 73±12* 28±1* 812±124*
0.25 147±24* 45±10* 697±460
0.5 13±33* 0±9* 58±40
1 0±2* 0±1* 87±92
2.5 0±13* 0±5* 39±45
5 6±22* 0±3* 2±2*
48 h Interferon gamma secreted in pg/mL (mean±S.D.)
[TBBPA] μM F-175 F-177 F-180
0 44±4 2513±78 436±2
0.05 746±19* 357±31* 151±32*
0.1 510±85* 457±140* 372±66
0.25 136±80 587±181* 264±30*
0.5 178±174 647±55* 233±11*
1 49±14 900±111* 409±41
2.5 0±6* 443±15* 122±17*
5 0±54 353±12* 132±5*
6 day Interferon gamma secreted in pg/mL (mean±S.D.)
[TBBPA] μM F-175 F-177 F-180
0 617±17 6917±146 210±14
0.05 668±10* 2525±2186 175±8*
0.1 593±32 2125±284* 127±2*
0.25 482±13* 2417±594* 115±4*
0.5 322±13* 1717±72* 95±3*
1 299±17* 871±51* 96±10*
2.5 96 ±35* 350±99* 49±2.5*
5 0±10* 133±31* 16±3*
Values are mean±S.D. of triplicate determinations,
*
indicates a significant difference from control (p<0.05).
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Table 6
Effects of 24 h, 48 h, 6 day exposures to TBBPA on IFNγ secretion from PBMCs cells
24 h Interferon gamma secreted in pg/mL (mean±S.D.)
[TBBPA] μM F186 F-187 F-188 F-193 F-194
0 65±8 101±7 647±12 333±3 525±18
0.05 59±4 126±16 330±201 474±91 532±248
0.1 73±0.9 121±6* 307±83* 239±55 532±54
0.25 72±22 111±15 447±140 150±47* 290±48*
0.5 55±8 108±4 287±12* 90±59* 182±38*
1 53±5 82±12 230±17* 69±27* 72±16*
2.5 72±8 178±37 203±21* 151±61* 93±33*
5 55±7 141±18* 83±6* 146±17* 95±5*
48 h Interferon gamma secreted in pg/mL (mean±S.D.)
[TBBPA] μM F-186 F-187 F-188 F-193 F-194
0 47±7 47±2 326±5 829±14 693±8
0.05 265±195 312±195 287±50 1083±62* 2250±58*
0.1 359±169 105±41 300±87 1050±45* 2767±55*
0.25 133±106 36±9 220±3* 1204±56* 493±14*
0.5 65±23 28±0.8* 114±10* 1471±26* 322±16*
1 45±5 30±2* 11±19* 629±19* 217±61*
2.5 53±5 55±1.5* 13±12* 717±38* 190±58*
5 40±5 64±0.8* 3±6* 471±19* 58±26*
6 day Interferon gamma secreted in pg/mL (mean±S.D.)
[TBBPA] μM F-186 F-187 F-188 F-193 F-194
0 68±4 58±0.6 370±9 644±19 1408±24
0.05 56±21 46±7 409±20 433±48* 1502±21*
0.1 114±9* 49±3* 363±23 396±23* 2503±68*
0.25 63±9 46±1.2* 198±2* 389±19* 1370±46
0.5 62±11 58±6 214±8* 259±6* 972±150*
1 51±3* 85±4* 92±13* 282±28* 667±29*
2.5 46±6* 48±2* 149±17* 356±44* 465±23*
5 34±0.9* 90±7* 93±12* 344±29* 62±18*
Values are mean±S.D. of triplicate determinations,
*
indicates a significant difference from contro (p<0.05).
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Table 7
Effects of 24 h exposure to HBCD +/− Pathway inhibitors on IFNγsecretion from MD-PBMCs.
NFκB Inhibitor (BAY 11-7085)
24 h Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM F-273 F-275 F-289 F-293
0 55±1 84±5 49±1 141±4
0 + BAY 21±1 59±4 20±2 23±5
0.5 97±4* 101±7* 37±5* 160±10
0.5 + BAY 86±16** 0±13** 9±1* 11±2*
1 150±6* 154±8* 52±1 168±10*
1 + BAY 62±11** 0±15** 11±0* 25±2
2.5 317±12* 180±9* 319±0.5* 441±37*
2.5 + BAY 46±13 90±21 126±3* 223±64*
MEK inhibitor (PD98059)
24 h Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM F-253 F-254 F-263 F-265
0 15±2 54±7 15±5 9±0.6
0 + PD 17±2 21±0.3 17±10 24±4
0.5 47±1* 88±3* 61±3* 56±6*
0.5+ PD 26±6 27±5 39±22 106±15**
1 74±0.8* 66±2 60±9* 46±6*
1 + PD 25±8 46±2** 66±10** 96±6**
2.5 111±7* 246±7* 119±6* 66±9*
2.5 + PD 42±0.4** 45±7** 69±13** 74±27
p38 Inhibitor (SB202190)
24 h Interferon gammasecreted in pg/mL (mean±S.D.)
[HBCD] μM F-254 F-255 F-263 F-265
0 35±0.6 11±3 269±13 75±3
0 + SB 6±0.3 11±4 52±10 125±55
0.5 80±5* 27±4* 5351±134* 1451±234*
0.5 + SB 54±4** 104±32** 956±363** 1292±133**
1 87±3* 20±2* 490±61* 1407±871
1+ SB 46±15** 69±8** 685±62** 1416±234**
2.5 121±9* 29±9* 1837±189* 348±131
2.5 + SB 16±3** 64±23** 639±86** 1473±95**
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JNK Inhibitor (BI78D3)
24 h Interferon gamma secreted in pg/mL (mean±S.D.)
[HBCD] μM F-271 F-273 F-275 F-278
0 65±4 116±5 19±0.7 45±46
0 + JNK 16±3 61±2 15±0.4 58±28
0.5 104±8* 203±14* 24±3 381±135*
0.5 + JNK 237±20** 119±13** 26±13 674±17**
1 251±44* 195±10* 24±0.8* 538±271
1+ JNK 306±69** 160±15** 23±1** 610±137**
2.5 140±13* 515±14* 40±3* 172±152
2.5 + JNK 53±1** 153±3** 31±3** 565±40**
Values are mean ± S.D. of triplicate determinations.
*
indicates a significant increase compared to no HBCD (0), p<0.05;
**
indicates a significant increase compared to no HBCD + inhibitor
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